Fig. 4: In vitro neutralization potency of anti-SARS-CoV-2 S VHH-Fcs. | Communications Biology

Fig. 4: In vitro neutralization potency of anti-SARS-CoV-2 S VHH-Fcs.

From: Arsenal of nanobodies shows broad-spectrum neutralization against SARS-CoV-2 variants of concern in vitro and in vivo in hamster models

Fig. 4: In vitro neutralization potency of anti-SARS-CoV-2 S VHH-Fcs.The alternative text for this image may have been generated using AI.

a Summary of IC50s obtained by surrogate (SVNA), pseudotyped (PVNA) and live (LVNA) virus neutralization assays against SARS-CoV-2 Wuhan. b Summary of IC50s obtained by SVNAs against SARS-CoV-2 variants Wuhan, Alpha, Beta, Gamma, Delta, Kappa and Omicron (B.1.1.529) and SARS-CoV. c Summary of IC50s obtained by LVNAs for VHH-Fcs against Wuhan, Alpha, Beta and Omicron SARS-CoV-2 variants. See also Table 2 for IC50 values. For Omicron LVNAs, only VHH-Fcs which were positive for binding to Omicron S by ELISA (see Fig. 2a) were included. Graphs were generated based on the data in Supplementary Figs. 14–18 and Supplementary Table 8. Black open circle, VHH-72 benchmark. VHHs are color-coded based on their epitope bin designation (see Fig. 1d).

Back to article page